Kestra Advisory Services’s Rein Therapeutics RNTX Stock Holding History

Kestra Advisory Services’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,500	Closed	-$6K	–	2360
2022 Q3	$6K	Hold	1,500	–	–	﹤0.01%	2090
2022 Q2	$8K	Hold	1,500	–	–	﹤0.01%	2112
2022 Q1	$15K	Hold	1,500	–	–	﹤0.01%	1985
2021 Q4	$17K	Hold	1,500	–	–	﹤0.01%	1995
2021 Q3	$31K	Hold	1,500	–	–	﹤0.01%	2097
2021 Q2	$38K	Hold	1,500	–	–	﹤0.01%	1986
2021 Q1	$43K	Hold	1,500	–	–	﹤0.01%	1834
2020 Q4	$33K	Buy	+1,500	New	+$37.5K	﹤0.01%	1831

Other funds holding RNTX

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Kestra Advisory Services's RNTX Position: Q4 2022 in Review

Kestra Advisory Services sold out of Rein Therapeutics (RNTX) in Q4 2022, closing a stake of 1,500 shares — an estimated $6K sold.

Kestra Advisory Services first reported a position in RNTX in Q4 2020 and held it in 8 quarters. The position peaked at $43K in Q1 2021. 19 funds tracked by Wall St. Rank hold RNTX as of Q4 2022.

Kestra Advisory Services reported no remaining Rein Therapeutics position as of Q4 2022 after selling out during the quarter.
Kestra Advisory Services sold 1,500 Rein Therapeutics shares in Q4 2022, an estimated $6K.
Kestra Advisory Services first reported a position in Rein Therapeutics in Q4 2020 and held it in 8 quarters.
Kestra Advisory Services's Rein Therapeutics position peaked at $43K in Q1 2021.
19 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2022.

Based on Kestra Advisory Services's 13F filing for Q4 2022, filed 31 Jan 2023.